If breast cancer has higher than normal levels of HER2 it is classified as HER2 positive. People with this type of breast cancer normally receive chemotherapy as well as targeted treatments, called ...

Pertuzumab, trade name Perjeta, can now be used in the treatment of HER2 positive metastatic breast cancer and in aggressive breast cancers which cannot be surgically removed. The drug was ...

9月13至17日，欧洲肿瘤内科学会（ESMO）年会在西班牙巴塞罗那盛大召开。会上，众多专家学者竞相展示肿瘤学领域的最新研究成果，共同推动肿瘤学科的全球发展。多项来自中国学者的学术成果在本次大会首次亮相，其中，由北京大学肿瘤医院沈琳教授担任主要 ...

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy. Treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) ...

Proteolytic Cleavage of HER2 (Ectodomain Shedding) & the Generation of Neoepitopes as New Biomarker Targets Proteolytic cleavage of HER2 (p185) has been demonstrated to result in a 95-kD (p95) CTF ...

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting.

which can be exploited to trigger receptor-mediated internalization and other downstream signal transduction.

Despite the well-established benefit of the standard taxane-trastuzumab-pertuzumab (THP) treatment regimen, the evolving landscape of HER2-positive breast cancer may offer new therapies and ...

Perjeta complements Herceptin in attacking HER2-positive tumours and we believe Perjeta will transform the way people with HER2-positive metastatic breast cancer are treated.” Hal Barron ...

HER2DX ® was evaluated in tumor samples from 214 patients with advanced HER2+ breast cancer treated with docetaxel, trastuzumab, and pertuzumab. The ERBB2 mRNA levels determined by HER2DX ® have ...